---
title: "Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292816164.md"
description: "Aldeyra Therapeutics plans to request a Type D meeting with the FDA by the end of Q3 2026. This follows clarification requests regarding minutes from a June 10, 2026, Type A meeting concerning its reproxalap NDA for dry eye disease. The upcoming Type D meeting aims to discuss the potential resubmission of the New Drug Application."
datetime: "2026-07-15T20:53:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292816164.md)
  - [en](https://longbridge.com/en/news/292816164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292816164.md)
generator: "portal-rs"
---

# Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission

**Aldeyra Therapeutics requested clarification on FDA minutes and plans a Type D meeting to discuss potential reproxalap NDA resubmission.**

**Key Highlights:**

-   Received FDA minutes from a June 10, 2026 Type A meeting regarding reproxalap NDA for dry eye disease.
-   On July 15, 2026 Aldeyra requested clarification of those minutes from the FDA.
-   Aldeyra intends to request a Type D meeting to discuss potential NDA resubmission.
-   Type D meeting is expected to occur by end of Q3 2026, advancing resubmission discussions.

Original SEC Filing: Aldeyra Therapeutics, Inc. \[ ALDX \] - 8-K - Jul. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ALDX.US](https://longbridge.com/en/quote/ALDX.US.md)

## Related News & Research

- [Research Analysts Issue Forecasts for ALDX Q3 Earnings](https://longbridge.com/en/news/296353895.md)
- [HC Wainwright Has Optimistic Outlook of ALDX FY2030 Earnings](https://longbridge.com/en/news/296224482.md)
- [Analyst Maintains Hold on Aldeyra Amid FDA Uncertainty Over Reproxalap’s Regulatory Path](https://longbridge.com/en/news/296099444.md)
- [EY Selects CrowdStrike to Power the Trust Layer of EY.ai Value Blueprints | CRWD Stock News](https://longbridge.com/en/news/297681656.md)
- [The common sense deficit hitting the City’s professional services firms](https://longbridge.com/en/news/297736194.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**